MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MEIP
CUSIPN/A
Phone858-369-7100
Debt
Debt-to-Equity RatioN/A
Current Ratio8.27
Quick Ratio8.27
Price-To-Earnings
Trailing P/E Ratio52.43
Forward P/E Ratio-4.59
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.25 million
Price / Sales5.97
Cash Flow$0.0764 per share
Price / Cash48.67
Book Value$1.38 per share
Price / Book2.70
Profitability
EPS (Most Recent Fiscal Year)$0.07
Net Income$2.67 million
Net Margins-1,651.87%
Return on Equity-60.75%
Return on Assets-54.49%
Miscellaneous
Employees25
Outstanding Shares37,320,000
Market Cap$135.86 million
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.08. The business earned $0.43 million during the quarter, compared to analysts' expectations of $0.40 million. MEI Pharma had a negative net margin of 1,651.87% and a negative return on equity of 60.75%. View MEI Pharma's Earnings History.
When is MEI Pharma's next earnings date?
What price target have analysts set for MEIP?
6 analysts have issued 1 year price targets for MEI Pharma's shares. Their predictions range from $6.50 to $12.00. On average, they anticipate MEI Pharma's stock price to reach $7.90 in the next year. This suggests a possible upside of 111.8% from the stock's current price. View Analyst Price Targets for MEI Pharma.
What is the consensus analysts' recommendation for MEI Pharma?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (7/18/2018)
- 2. Cann analysts commented, "We rate MEI Pharma, a development-stage biotechnology company working in epigenetics, the PI3K pathway and cancer metabolism, Outperform. We are increasing our price target to account for an increased average forward price-to-sales multiple of the biotechnology sector." (7/9/2018)
Are investors shorting MEI Pharma?
MEI Pharma saw a decline in short interest in July. As of July 13th, there was short interest totalling 1,048,693 shares, a decline of 41.6% from the June 29th total of 1,795,115 shares. Based on an average daily trading volume, of 270,489 shares, the short-interest ratio is presently 3.9 days. Currently, 1.9% of the shares of the stock are short sold. View MEI Pharma's Current Options Chain.
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include CannTrust (CNTTF), Aclaris Therapeutics (ACRS), Beyondspring (BYSI), Arcus Biosciences (RCUS), Arbutus Biopharma (ABUS), Lannett (LCI), Theratechnologies (THERF), Odonate Therapeutics (ODT), Kindred Biosciences (KIN), Five Prime Therapeutics (FPRX), Unum Therapeutics (UMRX), Rigel Pharmaceuticals (RIGL), Depomed (DEPO), Akebia Therapeutics (AKBA) and Forty Seven (FTSV).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold Ph.D., Pres, CEO & Director (Age 64)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 57)
- Mr. David M. Urso Esq., J.D., Sr. VP of Corp. Devel. and Gen. Counsel (Age 54)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 64)
- David A. Walsey, VP of IR & Corp. Communications
Has MEI Pharma been receiving favorable news coverage?
Media coverage about MEIP stock has trended somewhat positive on Friday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MEI Pharma earned a daily sentiment score of 0.21 on Accern's scale. They also assigned news coverage about the company an impact score of 46.69 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for MEI Pharma.
Who are MEI Pharma's major shareholders?
MEI Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vivo Capital LLC (17.69%), NEA Management Company LLC (15.33%), Boxer Capital LLC (7.81%), Renaissance Technologies LLC (5.95%), Sio Capital Management LLC (5.85%) and Millennium Management LLC (3.74%). Company insiders that own MEI Pharma stock include Charles V Baltic III and David M Urso. View Institutional Ownership Trends for MEI Pharma.
Which institutional investors are selling MEI Pharma stock?
MEIP stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., ClariVest Asset Management LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for MEI Pharma.
Which institutional investors are buying MEI Pharma stock?
MEIP stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, NEA Management Company LLC, Boxer Capital LLC, Millennium Management LLC, Sio Capital Management LLC, Acuta Capital Partners LLC, Renaissance Technologies LLC and Macquarie Group Ltd.. View Insider Buying and Selling for MEI Pharma.
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $3.73.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $135.86 million and generates $23.25 million in revenue each year. The company earns $2.67 million in net income (profit) each year or $0.07 on an earnings per share basis. MEI Pharma employs 25 workers across the globe.
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
